HomeCompareORINY vs QYLD

ORINY vs QYLD: Dividend Comparison 2026

ORINY yields 2.66% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QYLD wins by $5.2K in total portfolio value· pulled ahead in Year 8
10 years
ORINY
ORINY
● Live price
2.66%
Share price
$37.99
Annual div
$1.01
5Y div CAGR
-45.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.66
Full ORINY calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — ORINY vs QYLD

📍 QYLD pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORINYQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORINY + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORINY pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORINY
Annual income on $10K today (after 15% tax)
$226.00/yr
After 10yr DRIP, annual income (after tax)
$0.56/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, QYLD beats the other by $4,809.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORINY + QYLD for your $10,000?

ORINY: 50%QYLD: 50%
100% QYLD50/50100% ORINY
Portfolio after 10yr
$22.8K
Annual income
$2,829.99/yr
Blended yield
12.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORINY right now

ORINY
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
18.6
Piotroski
6/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORINY buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORINYQYLD
Forward yield2.66%11.92%
Annual dividend / share$1.01$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-45.3%0%
Portfolio after 10y$20.2K$25.4K
Annual income after 10y$0.66$5,659.31
Total dividends collected$324.00$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ORINY vs QYLD ($10,000, DRIP)

YearORINY PortfolioORINY Income/yrQYLD PortfolioQYLD Income/yrGap
1$10,845$145.43$10,352$1,192.36+$493.00ORINY
2$11,685$80.63$10,830$1,347.57+$855.00ORINY
3$12,548$44.41$11,460$1,539.07+$1.1KORINY
4$13,450$24.38$12,275$1,777.84+$1.2KORINY
5$14,405$13.36$13,323$2,078.95+$1.1KORINY
6$15,421$7.31$14,667$2,463.34+$754.00ORINY
7$16,504$4.00$16,396$2,960.57+$108.00ORINY
8← crossover$17,662$2.19$18,631$3,612.97$969.00QYLD
9$18,899$1.20$21,548$4,482.15$2.6KQYLD
10$20,223$0.66$25,398$5,659.31$5.2KQYLD

ORINY vs QYLD: Complete Analysis 2026

ORINYStock

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Full ORINY Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this ORINY vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORINY vs SCHDORINY vs JEPIORINY vs OORINY vs KOORINY vs MAINORINY vs XYLDORINY vs JEPQORINY vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.